ClinicalTrials.gg
RecruitingNCT07708142Updated Jul 16, 2026

Efficacy and Safety Evaluation of SMO1 in Patients With Retinal Vein Occlusive Macular Edema

A Phase 3 interventional study of Reference Drug and SMO1 in Retinal Vein Occlusion With Macular Edema, sponsored by SANGMYUNG innovation. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by SANGMYUNG innovation · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jan 2026, registered Jul 2026).
  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Macular Edema with a site in Korea, Republic of — 1 open to participants now, 2 under way, 1 of them phase 3. Macular Edema · Korea, Republic of.

Planned enrollment
11th of 35
312 · median 100
Started
2026
the only one that year
Phase 3
16 of 38
1 open now
Registered
38th of 38
by date

Among the 38 studies in Macular Edema with a site in Korea, Republic of, this one is the 11th largest by planned enrollment of the 35 interventional ones that give a count, is the only one that started in 2026, is one of 16 in phase 3, and was the 38th registered.

Macular Edema

759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 38 studies in Macular Edema with a site in Korea, Republic of is open now.

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Macular Edema with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-masked, parallel-group, active-controlled Phase 3 clinical trial designed to evaluate the efficacy and safety of SMO1 (Dexamethasone 700μg intravitreal implant) compared with the reference drug (Dexamethasone 700μg intravitreal implant) in patients with retinal vein occlusion (RVO)-associated macular edema.

Participants are randomized in a 1:1 ratio to receive either the reference drug or the investigational product, SMO1, following screening and baseline assesments. Randomization is centrally managed and stratified by RVO subtype (branch or central). Patients are followed for 6 months with scheduled visits to assess efficacy and safety endpoints. A total of 312 participants (156 per treatment arm) will be enrolled.

03

Conditions studied

  • Retinal Vein Occlusion With Macular Edema
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 19 years of age or older
  • A study eye diagnosed with macular edema following i) branch retinal vein occlusion (BRVO) within 12 months prior to the screening visit or; ii) central retinal vein occlusion (CRVO) within 9 months prior to the screening visit
  • A study eye with CRT measured to be 300μm or greater using OCT at the screening visit
  • A study eye with BCVA between 34 and 68 letters at the screening visit and the baseline (comparable to Snellen score between 20/200 and 20/50)
  • Provided written voluntarily after receiving a full explanation of the clinical trial

Exclusion criteria

Exclusion Criteria:

  • A study eye with visual improvement determined to be highly unlikely due to the baseline condition of the eye
  • A study eye with macular edema caused by the formation of an epiretinal membrane or visual improvement determined to be highly unlikely even if the macular edema decreases
  • A study eye with uncontrolled glaucoma with intraocular pressure of 25mmHg or higher despite medical treatment at the screening visit
  • A study eye with severe media opacity such as corneal opacity, cataracts, or vitreous hemorrhage
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
312 participants (estimated)

Study arms

  • Active comparator
    Reference Group

    Treatment: Reference Drug (Dexamethasone 700μg Intravitreal Implant) Pre-treatment: Ofloxacin (3mg/mL) Eye Drop

    Drug: Reference Drug

  • Experimental
    SMO1 Group

    Treatment: SMO1 (Dexamethasone 700μg Intravitreal Implant) Pre-treatment: Ofloxacin (3mg/mL) Eye Drop

    Drug: SMO1

Interventions

  • DrugReference Drug

    1. Pre-treatment: Ofloxacin Eye Drop TID for 3 days before and after the administration of the reference drug (Day -3 \~ 3). 2. Single administration of the reference drug at Day 0.

  • DrugSMO1

    1\. Pre-treatment: Ofloxacin Eye Drop TID for 3 days before and after the administration of the reference drug (Day -3 \~ 3). 2. Single administration of SMO1 at Day 0.

06

What researchers measure

Primary outcomes

  1. Best corrected visual acuity (BCVA) at Month 2

    Change in BCVA score from the baseline, at Month 2 after the administration of the investigational drug using early treatment diabetic retinopathy study (ETDRS) chart

    Time frame: Month 2

Secondary outcomes

  1. BCVA at Month 1, 3, and 6

    Change in BCVA score from the baseline, at Month 1, 3, and 6 after the administration of the investigational drug using ETDRS chart

    Time frame: Month 1, 3, and 6

  2. BCVA improvement of 15 letters (3 lines) or more

    Proportion of patients with BCVA improvement of 15 letters (3 lines) or more compared to the baseline using ETDRS chart, at each post-administration visit (Month 1, 2, 3, and 6)

    Time frame: Month 1, 2, 3, and 6

  3. Central retinal thickness (CRT) at each visit

    Change in CRT compared to the baseline measured with optical coherence tomography (OCT), at each post-administration visit (Month 1, 2, 3, and 6)

    Time frame: Month 1, 2, 3, and 6

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jul 2027, 18 months after the start.

Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's planned 18 months is below that.

Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2026
First posted
Jul 16, 2026
StartActual
Jan 29, 2026
Primary completionEst.
Jul 2027
CompletionEst.
Jan 2028
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07708142
Lead sponsor
SANGMYUNG innovation
Responsible party
Sponsor
First posted
Jul 16, 2026
Start date
Jan 29, 2026
Primary completion
Jul 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Jul 16, 2026

Study contacts

Nahyun Kang, Ph.D
Contact
nahyun.kang@sminnovation.com
+82 2-3489-6298

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion